Bridge Biotherapeutics

Developer of small molecule based therapeutics for the treatment of various diseases

placeSeongnam-si, Gyeonggi-do, South Korea calendar_todayFounded 2015 groups6 employees language bridgebiorx.com

Registered entities

Innovation

6 patent families (3 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 160 times.

YearFilings
20191
20202
20212
20223
20234
20243
20252

Investor mix

12 investors on record; lead investors include DAOL Investment, Lifecore Partners, KB Investment, SV Investment; 1 has since exited.

Investor typeCountShare
Venture capital758%
Private equity325%
Other / undisclosed217%
Coming soon